Columnists
Tipsheet
Cartoons
Podcasts
Newsletters
Sections
Podcasts
Townhall TV
Election
Capitol Voices
Entertainment
Radio News
Live Blog
Topics
Sites
Hot Air
PJ Media
Bearing Arms
Twitchy
RedState
JOIN VIP
LOGIN
MY ACCOUNT
Account Settings
Newsletter Subscriptions
Log Out
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Novabay Pharmaceuticals
(NY:
NBY
)
0.7560
UNCHANGED
Streaming Delayed Price
Updated: 8:00 PM EST, Nov 4, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Novabay Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
Next >
26 Stocks Moving in Thursday's Pre-Market Session
April 21, 2022
Gainers Redbox Entertainment Inc. (NASDAQ: RDBX) rose 31.9% to $3.35 in pre-market trading after jumping around 25% on Wednesday. Clarus Therapeutics Holdings, Inc. (NASDAQ:...
Via
Benzinga
23 Stocks Moving in Tuesday's Pre-Market Session
April 19, 2022
Gainers ToughBuilt Industries, Inc. (NASDAQ: TBLT) rose 44.9% to $0.2125 in pre-market trading as the company posted a narrower FY21 loss. Sharps Technology, Inc. (NASDAQ: STSS...
Via
Benzinga
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin Returns to QVC® to Discuss DERMAdoctor’s Eczema Treatment
April 11, 2022
From
NovaBay Pharmaceuticals, Inc
Via
Business Wire
NovaBay Pharmaceuticals Introduces Hydrating Cleansing Oil to its DERMAdoctor Calm Cool + Corrected Product Line
April 01, 2022
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals's Return On Capital Employed Insights
March 30, 2022
According to Benzinga Pro data, during Q4, NovaBay Pharmaceuticals (AMEX:NBY) posted sales of $2.64 million. Earnings were up 93.1%, but NovaBay Pharmaceuticals still reported an overall loss of...
Via
Benzinga
NovaBay Pharmaceuticals Reports 2021 Fourth Quarter and Full Year Financial Results
March 29, 2022
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
March 29, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Earnings Scheduled For March 29, 2022
March 29, 2022
Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is projected to report quarterly loss at $0.02 per share on revenue of $15.62 million.
Via
Benzinga
NovaBay Pharmaceuticals Earnings Preview
March 28, 2022
NovaBay Pharmaceuticals (AMEX:NBY) is set to give its latest quarterly earnings report on Tuesday, 2022-03-29. Here's what investors need to know before the announcement. Analysts estimate that NovaBay...
Via
Benzinga
The Week Ahead In Biotech (March 27-April 2): Lipocine, Akebia, Merck Await FDA Verdicts, Adcom Test For Amylyx, BioNTech Earnings And More
March 27, 2022
Biotech stocks reversed course in the week ending March 25, as an increase in risk appetite prompted traders to move money out of defensives and into risky bets.
Via
Benzinga
NovaBay Pharmaceuticals to Hold 2021 Fourth Quarter and Full Year Conference Call on March 29
March 22, 2022
From
NovaBay® Pharmaceuticals, Inc.
Via
Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
March 18, 2022
Good morning, trader! Let's start off the final day of the workweek right with a breakdown of the biggest pre-market stock movers for Friday!
Via
InvestorPlace
25 Stocks Moving in Friday's Pre-Market Session
March 18, 2022
Gainers Grom Social Enterprises, Inc. (NASDAQ: GROM) rose 60.5% to $1.53 in pre-market trading. StoneCo Ltd. (NASDAQ: STNE) shares rose 23.7% to $11.90 in pre-market trading...
Via
Benzinga
NovaBay Pharmaceuticals Chief Product Officer Dr. Audrey Kunin to Present DERMAdoctor Eczema Treatment as QVC® On-Air Guest
February 28, 2022
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals Engages Leading Chinese Marketing Firm to Drive Consumer Sales of DERMAdoctor Skincare Products in China
February 23, 2022
From
NovaBay Pharmaceuticals, Inc
Via
Business Wire
NovaBay Pharmaceuticals Announces Changes to Its Board of Directors
January 28, 2022
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals to Donate 2.5 Million KN95 Masks
January 20, 2022
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders
January 20, 2022
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals Expands Its Eyecare Product Portfolio With the Launch of Lubricating Eye Drops for the Immediate Relief of Dry Eye Symptoms
January 10, 2022
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
January 04, 2022
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals Holds Special Meeting of Stockholders
December 21, 2021
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
DERMAdoctor’s Calm Cool + Corrected Eczema Balm Receives National Eczema Association Seal of Acceptance
December 13, 2021
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals CEO Issues Letter to Stockholders
November 18, 2021
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals Reports Third Quarter 2021 Financial Results
November 11, 2021
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals Closes DERMAdoctor Acquisition
November 08, 2021
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals Closes $15.0 Million Private Placement
November 03, 2021
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals Announces Pricing of $15.0 Million Private Placement
November 01, 2021
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Pharmaceuticals Earnings Perspective: Return On Capital Employed
October 01, 2021
Benzinga Pro data, NovaBay Pharmaceuticals (AMEX:NBY) reported Q2 sales of $2.13 million. Earnings fell to a loss of $1.86 million, resulting in a 22.3% decrease from last...
Via
Benzinga
NovaBay Pharmaceuticals to Hold Conference Call and Webcast With Slide Presentation Today to Discuss Acquisition of DERMAdoctor
September 29, 2021
From
NovaBay Pharmaceuticals, Inc.
Via
Business Wire
NovaBay Acquires Skincare-Focused Firm For $15M
September 28, 2021
NovaBay Pharmaceuticals Inc (NYSE: NBY) has agreed to acquire DERMAdoctor LLC, a privately-held company that commercializes dermatologist-developed skincare...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.